|
|
 |
|
Viewing report
|
|
|
|
Juvenile Idiopathic Arthritis - Disease-Subtype Heterogeneity Drives Diverse Treatment Options
Decision Resources, Inc, Feb 2011, Pages: 32
The treatment of juvenile idiopathic arthritis (JIA) still leaves much to be desired. Despite the availability of treatments used in the adult arthritic population, JIA patients need therapies that are designed to treat the distinct subtypes of the disease and are suitable for use in children (e.g., drugs associated with less-painful injections). In addition, a proportion of JIA patients does not respond or responds suboptimally to treatment. These patients badly need an efficacious and safe therapy that will relieve the pain and other debilitating symptoms of JIA. Therapies tailored to the heterogeneity of JIA and its young patient population would experience significant uptake.
Questions answered in this report:
- JIA is a heterogeneous disease with multiple subtypes. How do treatments differ among subtypes? What are experts’ opinions on the best treatments for various subtypes?
- JIA treatments are identical to those used in adult rheumatic diseases. How is this relationship beneficial to JIA patients? How is it potentially detrimental? What factors do experts say most influence their treatment choices?
- Despite the presence of safe and efficacious treatments, unmet needs remain. What research is being done to discover treatments for these unmet needs? How do companies with emerging JIA therapies intend to meet some of these unmet needs?
Scope of the report:
- Overview of JIA and subtype-specific treatments: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic arthritis; systemic JIA; complications of JIA (uveitis and macrophage activation syndrome [MAS]); diagnosis of JIA.
- Epidemiology: Ten-year forecast (2009-2019) for United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
- Current JIA-indicated therapies: NSAIDs, corticosteroids, methotrexate, Enbrel, Humira, Orencia, and Actemra.
- Emerging/off-label therapies: Remicade, Simponi, Cimzia, Rituxan/MabThera, Kineret, Ilaris (canakinumab), Arcalyst (rilonacept).
- Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet needs
|
|
|
|
